EVFM - Evofem Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
EVFM price evolution
EVFM
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.53 | $3.98 | $9.04 | $21.47 |
| Short term investments | ||||
| Net receivables | $7.4 | $1.13 | $12.76 | $7.3 |
| Inventory | $5.48 | $5.38 | $5.18 | $5.95 |
| Total current assets | $16.51 | $12.7 | $31.79 | $41.91 |
| Long term investments | ||||
| Property, plant & equipment | $7.6 | $8.35 | $9.38 | $10.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.52 | $12.46 | $10.49 | $11.57 |
| Total investments | ||||
| Total assets | $26.03 | $25.16 | $42.28 | $53.47 |
| Current liabilities | ||||
| Accounts payable | $18.8 | $14.98 | $14.54 | $15.39 |
| Deferred revenue | ||||
| Short long term debt | $52.87 | $68 | $80.13 | $121.83 |
| Total current liabilities | $79.81 | $93.83 | $116.71 | $265.56 |
| Long term debt | $2.63 | $3.13 | $3.62 | $3.91 |
| Total noncurrent liabilities | $2.63 | $3.13 | $3.62 | $3.91 |
| Total debt | $55.49 | $71.13 | $83.75 | $125.74 |
| Total liabilities | $82.44 | $96.96 | $120.33 | $269.47 |
| Shareholders' equity | ||||
| Retained earnings | -$941.05 | -$938.69 | -$930.36 | -$1019.86 |
| Other shareholder equity | $64.99 | $49.53 | $36.96 | $1.59 |
| Total shareholder equity | -$56.4 | -$71.8 | -$78.04 | -$216 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.98 | $12.79 | $71.45 | $15.88 |
| Short term investments | $8.23 | |||
| Net receivables | $1.13 | $6.45 | $1.07 | $0.7 |
| Inventory | $5.38 | $7.67 | $7.16 | |
| Total current assets | $12.7 | $30.14 | $97.73 | $26.42 |
| Long term investments | ||||
| Property, plant & equipment | $8.35 | $11.17 | $11.19 | $0.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.46 | $12.37 | $12.24 | $1.87 |
| Total investments | $8.23 | |||
| Total assets | $25.16 | $42.51 | $109.97 | $28.3 |
| Current liabilities | ||||
| Accounts payable | $14.98 | $10.32 | $10.64 | $6.01 |
| Deferred revenue | ||||
| Short long term debt | $68 | $111.26 | $54.7 | $0.2 |
| Total current liabilities | $93.83 | $137.66 | $77.28 | $12.66 |
| Long term debt | $3.13 | $4.42 | $31.24 | |
| Total noncurrent liabilities | $3.13 | $4.42 | $31.34 | |
| Total debt | $71.13 | $115.68 | $85.94 | $0.2 |
| Total liabilities | $96.96 | $142.09 | $108.62 | $12.66 |
| Shareholders' equity | ||||
| Retained earnings | -$938.69 | -$860.68 | -$655.49 | -$513.18 |
| Other shareholder equity | $49.53 | $5.09 | ||
| Total shareholder equity | -$71.8 | -$104.31 | $1.35 | $15.64 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.81 | $0.18 | $6.37 | $6.03 |
| Cost of revenue | $1.38 | $0.38 | $1.68 | $1.28 |
| Gross Profit | $4.43 | -$0.2 | $4.69 | $4.75 |
| Operating activities | ||||
| Research & development | $0.54 | $1.69 | $5.21 | $7.74 |
| Selling, general & administrative | $7.47 | $10.16 | $18.21 | $21.42 |
| Total operating expenses | $8.01 | $11.85 | $23.41 | $29.17 |
| Operating income | -$3.58 | -$12.05 | -$18.72 | -$24.42 |
| Income from continuing operations | ||||
| EBIT | -$2.35 | -$8.33 | $89.52 | -$125.96 |
| Income tax expense | $0 | $0.01 | $0.01 | $0.02 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$2.35 | -$8.34 | $89.51 | -$125.98 |
| Income (for common shares) | -$2.35 | -$11.48 | $89.51 | -$124.07 |
| (in millions $) | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16.84 | $0.45 | ||
| Cost of revenue | $4.42 | $0.47 | ||
| Gross Profit | $12.42 | -$0.02 | ||
| Operating activities | ||||
| Research & development | $25.03 | $17.05 | $22.23 | |
| Selling, general & administrative | $71.51 | $86.55 | $30.51 | |
| Total operating expenses | $96.55 | $103.6 | $52.74 | |
| Operating income | -$84.12 | -$103.62 | -$52.74 | |
| Income from continuing operations | ||||
| EBIT | -$76.65 | -$142.31 | -$80.03 | |
| Income tax expense | $0.04 | $0 | $0 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$76.7 | -$142.31 | -$80.03 | |
| Income (for common shares) | -$78.01 | -$142.31 | -$80.03 | |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$2.35 | -$8.34 | $89.51 | -$125.98 |
| Operating activities | ||||
| Depreciation | $0.24 | $0.25 | $0.25 | $0.25 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.42 | $0.18 | $0.98 | $1.08 |
| Total cash flows from operations | -$4.94 | -$6.53 | -$16.3 | -$26.66 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.04 | -$0.07 | -$0.17 |
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.04 | -$0.07 | -$0.17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.06 | $4.29 | $47.76 | |
| Net borrowings | $1.64 | $1.5 | -$5.89 | |
| Total cash flows from financing | $1.7 | $1.5 | $3.95 | $41.36 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.24 | -$5.07 | -$12.42 | $14.53 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$76.7 | -$205.19 | -$142.31 | -$80.03 |
| Operating activities | ||||
| Depreciation | $1.01 | $1.02 | $0.3 | $0.26 |
| Business acquisitions & disposals | $0.25 | $0.25 | $0.25 | |
| Stock-based compensation | $3.31 | $8.9 | $12.7 | $8.58 |
| Total cash flows from operations | -$70.41 | -$146.67 | -$104.83 | -$55.1 |
| Investing activities | ||||
| Capital expenditures | -$0.34 | -$2.94 | -$2.25 | -$0.13 |
| Investments | $8.23 | -$8.23 | ||
| Total cash flows from investing | -$0.34 | -$2.69 | $6.23 | -$8.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.53 | $81.99 | $107.97 | $84.94 |
| Net borrowings | $5.61 | $48.94 | -$4.01 | |
| Total cash flows from financing | $61.94 | $90.69 | $154.23 | $78.08 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8.81 | -$58.66 | $55.63 | $14.86 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $18.39M |
|---|---|
| EBITDA | -$46.13M |
| EBIT | -$47.12M |
| Net Income | -$47.16M |
| Revenue Q/Q | 36.65% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -128.38% |
| ROE | 44.68% |
| Debt/Equity | -1.35 |
|---|---|
| Net debt/EBITDA | -1.75 |
| Current ratio | 0.21 |
| Quick ratio | 0.14 |